HIMS & HERS HEALTH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - HIMS
28 juni, 04:41
HIMS & HERS HEALTH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - HIMS
PR Newswire
NEW ORLEANS, June 27, 2025
NEW ORLEANS , June 27, 2025 /PRNewswire/ -- ClaimsFiler , a FREE shareholder information service, reminds investors that they have until August 25, 2025 to file lead plaintiff applications in securities class action lawsuits against Hims & Hers Health , Inc. ("Hims" or the "Company") (NYSE: HIMS), if they purchased the Company's securities between April 29, 2025 and June 23, 2025 , inclusive (the "Class Period"). These actions are pending in the United States District Court for the Northern District of California .
Get Help
Hims investors should visit us at https://claimsfiler.com/cases/nyse-hims/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
About the Lawsuit
Hims & Hers and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On June 23, 2025 , Novo Nordisk announced that it was terminating its partnership with Hims, disclosing that the Company had "failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk," and that "the 'semaglutide' active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies" may contain "unsafe and illicit foreign ingredients."
On this news, the price of Hims' shares fell $22.24 , or 34.6%, to close at $41.98 per share on June 23, 2025 , on unusually heavy trading volume.
The first-filed case is Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315. A subsequent case, Yaghsizian v. Hims & Hers Health, Inc. , No. 25-cv-05321, expanded the class period.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com .
SOURCE ClaimsFiler
Ämnen i artikeln
HIMS & HERS HEALTH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - HIMS
28 juni, 04:41
HIMS & HERS HEALTH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - HIMS
PR Newswire
NEW ORLEANS, June 27, 2025
NEW ORLEANS , June 27, 2025 /PRNewswire/ -- ClaimsFiler , a FREE shareholder information service, reminds investors that they have until August 25, 2025 to file lead plaintiff applications in securities class action lawsuits against Hims & Hers Health , Inc. ("Hims" or the "Company") (NYSE: HIMS), if they purchased the Company's securities between April 29, 2025 and June 23, 2025 , inclusive (the "Class Period"). These actions are pending in the United States District Court for the Northern District of California .
Get Help
Hims investors should visit us at https://claimsfiler.com/cases/nyse-hims/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
About the Lawsuit
Hims & Hers and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On June 23, 2025 , Novo Nordisk announced that it was terminating its partnership with Hims, disclosing that the Company had "failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk," and that "the 'semaglutide' active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies" may contain "unsafe and illicit foreign ingredients."
On this news, the price of Hims' shares fell $22.24 , or 34.6%, to close at $41.98 per share on June 23, 2025 , on unusually heavy trading volume.
The first-filed case is Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315. A subsequent case, Yaghsizian v. Hims & Hers Health, Inc. , No. 25-cv-05321, expanded the class period.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com .
SOURCE ClaimsFiler
Ämnen i artikeln
Börsen idag
-1-992x558.webp&w=3840&q=75)
-992x558.webp&w=3840&q=75)
-992x558.webp&w=3840&q=75)
Börsen idag
Mest läst
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
